Progress in Medicinal Chemistry
- 1st Edition, Volume 59 - April 30, 2020
- Latest edition
- Editors: David R. Witty, Brian Cox
- Language: English
Progress in Medicinal Chemistry, Volume 59, provides a review of eclectic developments in medicinal G139 chemistry. Each chapter is written by an international board of authors,… Read more
World Book Day celebration
Where learning shapes lives
Up to 25% off trusted resources that support research, study, and discovery.
Description
Description
Progress in Medicinal Chemistry, Volume 59, provides a review of eclectic developments in medicinal G139 chemistry. Each chapter is written by an international board of authors, with this release focusing on Small Molecules - Giant Leaps for Immuno-Oncology, Reviewing P2X7, Reviewing ASK1, and Reviewing DNA-encoded libraries.
Key features
Key features
- Provides extended, timely reviews of topics in medicinal chemistry
- Contains targets and technologies relevant to the discovery of tomorrow’s drugs
- Presents analyses of successful drug discovery programs
Readership
Readership
Everyone interested in the strategy and practice of the preclinical phases of the creation of new medicines. Those wishing to understand the drivers of drug design or expand their knowledge of therapeutic target classes
Table of contents
Table of contents
- Small molecules—Giant leaps for immuno-oncology
- P2X7 receptor antagonists for the treatment of systemic inflammatory disorders
- Discovery and development of ASK1 inhibitors
- An overview of DNA-encoded libraries—A versatile tool for drug discovery
Lisa Kötzner, Bayard Huck, Sakshi Garg and Klaus Urbahns
Christine F. Gelin, Anindya Bhattacharya and Michael A. Letavic
Reginald Brys, Karl Gibson, Tanja Poljak, Steven Van Der Plas and David Amantini
Daniel Madsen, Carlos Azevedo, Iolanda Micco, Lars Kolster Petersen and Nils Jakob Vest Hansen
Product details
Product details
- Edition: 1
- Latest edition
- Volume: 59
- Published: May 5, 2020
- Language: English
About the editors
About the editors
DW
David R. Witty
In 2010 David and several colleagues successfully raised $35M in venture funding to found Convergence Pharmaceuticals, a specialist ion channel company focused on the development of novel treatments for pain, based in Cambridge UK. David presently leads their discovery programme and manages scientific operations within the business.
David is chairman of the Fine Chemicals Group of the Society of Chemical Industry, with responsibility for the delivery of conferences, seminars and training courses for chemists throughout the UK and Europe, and advising parliamentary bodies on matters of relevance to the UK chemical industry.
Since 2008 David has been a STEM ambassador for SETPOINT, introducing school students at both primary and secondary level to the excitement and possibilities of pursuing scientific careers, through workshops, lectures and competitions.
BC